Rain Oncology Inc. Common Stock
RAIN
RAIN was delisted on the 25th of January, 2024.
40 hedge funds and large institutions have $233M invested in Rain Oncology Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 40 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
80.73% more ownership
Funds ownership: 0% → 80.73% (+81%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$46M |
| 2 |
PA
Perceptive Advisors
New York
|
+$44.5M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$34.1M |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$28.7M |
| 5 |
Janus Henderson Group
London,
|
+$25.5M |
Top Sellers
RAIN Hedge Fund Activity: Q2 2021 in Review
40 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Rain Oncology Inc. Common Stock (RAIN) for Q2 2021, worth a combined $233M.
Buyers outnumbered sellers: 40 funds opened new RAIN positions and 0 closed out — a net gain of 40 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $46M.
- 40 institutional investors held Rain Oncology Inc. Common Stock (RAIN) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $233M of Rain Oncology Inc. Common Stock stock for Q2 2021.
- 40 funds opened new Rain Oncology Inc. Common Stock positions in Q2 2021 and 0 closed out, a net change of +40 holders.
- The largest Rain Oncology Inc. Common Stock buyer in Q2 2021 was Cormorant Asset Management, an estimated $46M added.
Based on aggregated 13F filings for Q2 2021.